Efficacy and safety of Anluohuaxian in the treatment of patients with severe Coronavirus disease 2019- a multicenter, open label, randomized controlled study: a structured summary of a study protocol for a randomised controlled trial
Letter
[키워드] 6-minute walking distance
actual
Alpha
analyst
Anluohuaxian
antiviral drugs
brand
bronchial asthma
Care
change
changes
Chinese
Chinese herbal medicines
chronic obstructive
Colchicine
Combined
completion
Compliance
composed
computer tomography
Confirmed
connective tissue
control group
Coronavirus disease 2019
COVID-19
criteria
Cyclophosphamide
cytokine
diagnosed
dissemination
distribution
drug
Efficacy and safety
element
Endocrine
enrolled
Estimated
evaluate
expected
experimental group
explained
facilitate
fibrosis
glucocorticoid
groups
hepatic fibrosis
High-resolution
history
Hormones
HRCT
Huoshenshan Hospital
Imatinib
include
indicate
interferon-γ
interstitial
Interstitial lung disease
investigators
involved
IWRS
Kidney disease
lactating
liver
lobular
lung
maximum
Mental Disorders
minimum
multicenter
Nasopharyngeal swab
Necrosis
negative
neurologic
Nintedanib
nodule
not blinded
nucleic acid test
number
objective
open label
outcome
outcome assessors
participant
Participants
Pathogenesis
pathway
Patient
pharmaceutical
pill
professional
proportion
protocol
provided
pulmonary
pulmonary disease
pulmonary fibrosis
random
randomised
randomised controlled trial
randomization
randomization system
Randomized
Randomized controlled trial
randomly divided
RCT
recruitment
Research
research drug
respiratory specimen
Sample size
Science
second
selected
severe COVID-19
sputum
statistical
status
Study protocol
subject
technology
therapeutic drug
Tongji Hospital
treated
Treatment
treatment group
Trial
Union Hospital
university
variety
website
West
Wuhan
Year
[DOI] 10.1186/s13063-020-04399-8 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04399-8 PMC 바로가기 [Article Type] Letter